553 – Test 1 Quiz
All chapters included; minimum of 10 questions per chapter; each question followed by
correct answer and rationale.
Chapter 1: Drug Development, Regulation, and Prescribing Law
1. A nurse practitioner is reviewing a new drug application and wants to know which clinical trial phase
primarily confirms efficacy and monitors adverse effects in a larger population before approval. Which phase
is this?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct answer: C. Phase III
Rationale: Phase III trials are large, controlled studies used to confirm efficacy, compare
treatments, and monitor adverse effects before FDA approval.
2. A manufacturer is studying a new medication in a small group of healthy volunteers to evaluate safety,
dosage range, and pharmacokinetics. Which phase is being conducted?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct answer: A. Phase I
Rationale: Phase I studies focus on initial human exposure, safety, dose range, and
pharmacokinetics, usually in healthy volunteers.
3. A patient asks why her generic medication can be substituted for the brand-name product. Which
explanation is most accurate?
A. The generic has the same color and scoring as the brand.
B. The generic must demonstrate similar AUC and Cmax within the accepted
bioequivalence range.
C. The generic must be manufactured by the brand company.
D. The generic must cost at least 50% less than the brand.
, Correct answer: B. The generic must demonstrate similar AUC and Cmax within the
accepted bioequivalence range.
Rationale: Generic drugs must meet bioequivalence standards showing similar rate and
extent of absorption, commonly assessed with AUC and Cmax.
4. Which regulatory program is designed to manage serious medication risks through measures such as
prescriber certification, patient monitoring, or restricted dispensing?
A. DEA scheduling
B. REMS
C. Orange Book rating
D. MedWatch
Correct answer: B. REMS
Rationale: A Risk Evaluation and Mitigation Strategy, or REMS, is used when a drug has
serious risks that require extra safeguards beyond labeling.
5. A medication for a serious condition is approved using surrogate endpoints while additional confirmatory
studies are still required. Which pathway best describes this approval?
A. Compassionate use
B. Accelerated approval
C. Over-the-counter switch
D. Abbreviated new drug approval
Correct answer: B. Accelerated approval
Rationale: Accelerated approval allows earlier approval for serious conditions based on
surrogate markers, with postmarketing confirmatory studies required.
6. Which schedule of controlled substances has accepted medical use but the highest abuse potential among
scheduled drugs?
A. Schedule I
B. Schedule II
C. Schedule III
D. Schedule IV
Correct answer: B. Schedule II
Rationale: Schedule II drugs have accepted medical use but high abuse potential that
may lead to severe psychological or physical dependence.
7. A prescriber is completing a prescription for a controlled medication. Which element is essential for a
legally complete prescription?
A. Patient height and BMI
, B. DEA number when required for the medication being prescribed
C. Employer name
D. Insurance group number
Correct answer: B. DEA number when required for the medication being prescribed
Rationale: Controlled substance prescriptions must include the prescriber’s DEA number
and the standard elements needed for a complete prescription.
8. A nurse practitioner wants to report a serious adverse drug event observed after a new medication was
started. Which FDA program is specifically used for this purpose?
A. Orange Book
B. MedWatch
C. REMS
D. 340B
Correct answer: B. MedWatch
Rationale: MedWatch is the FDA safety reporting program used by clinicians and
consumers to report adverse events and product problems.
9. Which statement best describes a boxed warning, often called a black box warning?
A. It lists all common side effects in alphabetical order.
B. It identifies the least serious adverse effects of a medication.
C. It is the FDA’s strongest warning for serious or life-threatening drug risks.
D. It is required only for over-the-counter medications.
Correct answer: C. It is the FDA’s strongest warning for serious or life-threatening drug
risks.
Rationale: A boxed warning is the FDA’s strongest safety warning and highlights serious
or potentially life-threatening risks.
10. A patient receives a refill for a Schedule III medication. Which feature best distinguishes Schedule III
drugs from Schedule II drugs?
A. Schedule III drugs have no accepted medical use.
B. Schedule III drugs have lower abuse potential than Schedule II drugs.
C. Schedule III drugs cannot be called in by prescribers.
D. Schedule III drugs never cause physical dependence.
Correct answer: B. Schedule III drugs have lower abuse potential than Schedule II drugs.
Rationale: Schedule III medications have accepted medical use and lower abuse
potential than Schedule II medications, though misuse and dependence can still occur.
, Chapter 2: Pharmacokinetics and Pharmacodynamics
11. A hospitalized patient needs immediate drug effect and complete systemic availability. Which route best
provides 100% bioavailability?
A. Oral
B. Rectal
C. Intravenous
D. Subcutaneous
Correct answer: C. Intravenous
Rationale: Intravenous administration delivers drug directly into the systemic circulation,
producing 100% bioavailability.
12. A medication has a half-life of 8 hours and is given repeatedly at regular intervals. Assuming first-order
kinetics, when will steady state usually be reached?
A. After 8 hours
B. After 16 hours
C. After 24 to 40 hours
D. After 72 hours regardless of half-life
Correct answer: C. After 24 to 40 hours
Rationale: Most drugs reach steady state after about 3 to 5 half-lives. With an 8-hour
half-life, that is about 24 to 40 hours.
13. Which pharmacokinetic term refers to the fraction of a dose that reaches the systemic circulation?
A. Clearance
B. Volume of distribution
C. Bioavailability
D. Potency
Correct answer: C. Bioavailability
Rationale: Bioavailability describes the fraction or percentage of drug that reaches the
systemic circulation after administration.
14. A weakly acidic drug is given orally to a neonate with relatively alkaline gastric pH. What effect is most
likely?
A. Increased absorption because more drug is nonionized
B. Decreased absorption because more drug is ionized
C. No change because pH does not affect absorption
All chapters included; minimum of 10 questions per chapter; each question followed by
correct answer and rationale.
Chapter 1: Drug Development, Regulation, and Prescribing Law
1. A nurse practitioner is reviewing a new drug application and wants to know which clinical trial phase
primarily confirms efficacy and monitors adverse effects in a larger population before approval. Which phase
is this?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct answer: C. Phase III
Rationale: Phase III trials are large, controlled studies used to confirm efficacy, compare
treatments, and monitor adverse effects before FDA approval.
2. A manufacturer is studying a new medication in a small group of healthy volunteers to evaluate safety,
dosage range, and pharmacokinetics. Which phase is being conducted?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct answer: A. Phase I
Rationale: Phase I studies focus on initial human exposure, safety, dose range, and
pharmacokinetics, usually in healthy volunteers.
3. A patient asks why her generic medication can be substituted for the brand-name product. Which
explanation is most accurate?
A. The generic has the same color and scoring as the brand.
B. The generic must demonstrate similar AUC and Cmax within the accepted
bioequivalence range.
C. The generic must be manufactured by the brand company.
D. The generic must cost at least 50% less than the brand.
, Correct answer: B. The generic must demonstrate similar AUC and Cmax within the
accepted bioequivalence range.
Rationale: Generic drugs must meet bioequivalence standards showing similar rate and
extent of absorption, commonly assessed with AUC and Cmax.
4. Which regulatory program is designed to manage serious medication risks through measures such as
prescriber certification, patient monitoring, or restricted dispensing?
A. DEA scheduling
B. REMS
C. Orange Book rating
D. MedWatch
Correct answer: B. REMS
Rationale: A Risk Evaluation and Mitigation Strategy, or REMS, is used when a drug has
serious risks that require extra safeguards beyond labeling.
5. A medication for a serious condition is approved using surrogate endpoints while additional confirmatory
studies are still required. Which pathway best describes this approval?
A. Compassionate use
B. Accelerated approval
C. Over-the-counter switch
D. Abbreviated new drug approval
Correct answer: B. Accelerated approval
Rationale: Accelerated approval allows earlier approval for serious conditions based on
surrogate markers, with postmarketing confirmatory studies required.
6. Which schedule of controlled substances has accepted medical use but the highest abuse potential among
scheduled drugs?
A. Schedule I
B. Schedule II
C. Schedule III
D. Schedule IV
Correct answer: B. Schedule II
Rationale: Schedule II drugs have accepted medical use but high abuse potential that
may lead to severe psychological or physical dependence.
7. A prescriber is completing a prescription for a controlled medication. Which element is essential for a
legally complete prescription?
A. Patient height and BMI
, B. DEA number when required for the medication being prescribed
C. Employer name
D. Insurance group number
Correct answer: B. DEA number when required for the medication being prescribed
Rationale: Controlled substance prescriptions must include the prescriber’s DEA number
and the standard elements needed for a complete prescription.
8. A nurse practitioner wants to report a serious adverse drug event observed after a new medication was
started. Which FDA program is specifically used for this purpose?
A. Orange Book
B. MedWatch
C. REMS
D. 340B
Correct answer: B. MedWatch
Rationale: MedWatch is the FDA safety reporting program used by clinicians and
consumers to report adverse events and product problems.
9. Which statement best describes a boxed warning, often called a black box warning?
A. It lists all common side effects in alphabetical order.
B. It identifies the least serious adverse effects of a medication.
C. It is the FDA’s strongest warning for serious or life-threatening drug risks.
D. It is required only for over-the-counter medications.
Correct answer: C. It is the FDA’s strongest warning for serious or life-threatening drug
risks.
Rationale: A boxed warning is the FDA’s strongest safety warning and highlights serious
or potentially life-threatening risks.
10. A patient receives a refill for a Schedule III medication. Which feature best distinguishes Schedule III
drugs from Schedule II drugs?
A. Schedule III drugs have no accepted medical use.
B. Schedule III drugs have lower abuse potential than Schedule II drugs.
C. Schedule III drugs cannot be called in by prescribers.
D. Schedule III drugs never cause physical dependence.
Correct answer: B. Schedule III drugs have lower abuse potential than Schedule II drugs.
Rationale: Schedule III medications have accepted medical use and lower abuse
potential than Schedule II medications, though misuse and dependence can still occur.
, Chapter 2: Pharmacokinetics and Pharmacodynamics
11. A hospitalized patient needs immediate drug effect and complete systemic availability. Which route best
provides 100% bioavailability?
A. Oral
B. Rectal
C. Intravenous
D. Subcutaneous
Correct answer: C. Intravenous
Rationale: Intravenous administration delivers drug directly into the systemic circulation,
producing 100% bioavailability.
12. A medication has a half-life of 8 hours and is given repeatedly at regular intervals. Assuming first-order
kinetics, when will steady state usually be reached?
A. After 8 hours
B. After 16 hours
C. After 24 to 40 hours
D. After 72 hours regardless of half-life
Correct answer: C. After 24 to 40 hours
Rationale: Most drugs reach steady state after about 3 to 5 half-lives. With an 8-hour
half-life, that is about 24 to 40 hours.
13. Which pharmacokinetic term refers to the fraction of a dose that reaches the systemic circulation?
A. Clearance
B. Volume of distribution
C. Bioavailability
D. Potency
Correct answer: C. Bioavailability
Rationale: Bioavailability describes the fraction or percentage of drug that reaches the
systemic circulation after administration.
14. A weakly acidic drug is given orally to a neonate with relatively alkaline gastric pH. What effect is most
likely?
A. Increased absorption because more drug is nonionized
B. Decreased absorption because more drug is ionized
C. No change because pH does not affect absorption
